HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept
{
"count": 380,
"next": "http://api.gregory-ms.com/trials/source/12/?page=3",
"previous": "http://api.gregory-ms.com/trials/source/12/",
"results": [
{
"title": "Ocrelizuamb for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.",
"summary": "<b>Conditions</b>: Radiologically Isolated Syndrome; Multiple Sclerosis<br/><b>Interventions</b>: Drug: Ocrelizumab; Other: Placebo<br/><b>Sponsors</b>: Yale University; Genentech, Inc.<br/><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT04877457?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14",
"published_date": "2021-05-07T16:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2021-05-07T11:43:30Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis",
"summary": "<b>Condition</b>: Multiple Sclerosis, Relapsing-Remitting<br/><b>Intervention</b>: Drug: Natalizumab<br/><b>Sponsor</b>: Biogen<br/><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05265728?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-03-03T17:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-03-03T12:52:45Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "The Effect of Iyengar Yoga Practice on Patients With Multiple Sclerosis",
"summary": "<b>Conditions</b>: Multiple Sclerosis; Iyengar Yoga; Yoga; EDSS<br/><b>Intervention</b>: Other: The effect of Iyengar yoga practice on patients with multiple sclerosis<br/><b>Sponsor</b>: University Hospital, Motol<br/><b>Active, not recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05247372?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-02-18T17:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-02-18T13:53:27Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "Figure of 8 Walk Test in Multiple Sclerosis",
"summary": "<b>Condition</b>: Multiple Sclerosis<br /><b>Intervention</b>: Other: Assesment<br /><b>Sponsor</b>: Kahramanmaras Sutcu Imam University<br /><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05433714?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-06-27T16:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-06-27T13:30:06.486520Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt",
"summary": "<b>Condition</b>: Relapsing-Remitting Multiple Sclerosis<br /><b>Intervention</b>: Drug: Fingolimod<br /><b>Sponsor</b>: Hikma Pharmaceuticals LLC<br /><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05423769?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-06-20T16:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-06-21T14:30:07.076364Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "Sensing Physical Activity to Evaluate and Monitor a Routine Aftercare Program (SensE-M)",
"summary": "<b>Condition</b>: Disease With a Risk for Chronicity<br/><b>Intervention</b>: <br/><b>Sponsors</b>: University of Zurich; Kliniken Valens<br/><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05243407?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-02-17T17:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-02-17T12:33:27Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis",
"summary": "<b>Condition</b>: Multiple Sclerosis<br/><b>Intervention</b>: Device: partial-body cryotherapy chamber session<br/><b>Sponsors</b>: Fondation Ildys; Lille Catholic University<br/><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05219201?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-02-01T17:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-02-01T14:57:18Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "Designing Virtual Reality-based Software for People With Multiple Sclerosis",
"summary": "<b>Condition</b>: Multiple Sclerosis<br /><b>Intervention</b>: Other: Exergaming<br /><b>Sponsors</b>: Yuzuncu Yıl University; Dokuz Eylul University<br /><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05420532?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-06-15T16:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-06-15T11:10:05.936487Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants",
"summary": "<b>Condition</b>: Multiple Sclerosis<br/><b>Intervention</b>: Drug: Natalizumab<br/><b>Sponsors</b>: Biogen; Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse<br/><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05236777?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-02-11T17:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-02-11T14:03:27Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
},
{
"title": "Promoting Aerobic Training in Multiple Sclerosis",
"summary": "<b>Condition</b>: Multiple Sclerosis<br/><b>Interventions</b>: Behavioral: Aerobic exercise; Behavioral: Task-oriented upper-limb training; Behavioral: Sport events participation<br/><b>Sponsors</b>: Fondazione Italiana Sclerosi Multipla; University of Genoa; University Grenoble Alps<br/><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/ct2/show/NCT05212805?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2022-01-28T17:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"discovery_date": "2022-01-28T15:57:18Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null
}
]
}